Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tivic Health Systems, Inc.

6.47
-0.6500-9.13%
Post-market: 6.480.0100+0.15%19:59 EDT
Volume:261.66K
Turnover:1.81M
Market Cap:4.01M
PE:-0.33
High:6.95
Open:6.93
Low:6.30
Close:7.12
Loading ...

Tivic Health Systems Inc -on Mar 18, Enters Equity Purchase Agreement With Mast Hill Fund - SEC Filing

THOMSON REUTERS
·
22 Mar

Tivic Health Systems FY24 EPS $(19.68); Revenue $780K Down From $1.176M YoY

Benzinga
·
22 Mar

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

THOMSON REUTERS
·
22 Mar

Press Release: Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

Dow Jones
·
22 Mar

Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

Business Wire
·
14 Mar

Tivic Health Systems Inc trading halted, news pending

TIPRANKS
·
07 Mar

Tivic Health announces new non-invasive vagus nerve stimulation method data

TIPRANKS
·
06 Mar

Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System

Business Wire
·
06 Mar

BRIEF-Tivic Health Systems Announces Reverse Stock Split

Reuters
·
05 Mar

Tivic Health Systems, Inc. Announces Reverse Stock Split

THOMSON REUTERS
·
05 Mar

Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve

Business Wire
·
03 Mar

Former Statera CEO Michael Handley named Tivic Biopharma president

TIPRANKS
·
24 Feb

Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

Business Wire
·
24 Feb

BUZZ-Tivic Health Systems rises after deal for late-stage immunotherapy drug

Reuters
·
13 Feb

Crude Oil Down Over 2%; Upstart Shares Jump Following Earnings

Benzinga
·
13 Feb

Tivic Health Systems Secures Licensing Agreement with Statera

TIPRANKS
·
12 Feb

Tivic Health acquires exclusive rights to Entolimod from Statera BioPharma

TIPRANKS
·
12 Feb

BRIEF-Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist

Reuters
·
12 Feb

Tivic Health Systems Inc - to Pay Statera $1.2 Million in Equity and $300,000 Cash for Entolimod

THOMSON REUTERS
·
12 Feb

Tivic Health Acquires Exclusive Worldwide Rights to Phase Iii Tlr5 Agonist From Statera Biopharma

THOMSON REUTERS
·
12 Feb